Baird analyst Eric Coldwell said they have long posited that Cardinal Health could well absorb the loss of OptumRx given strong underlying market fundamentals, recent performance, and solid BS/CF generation; and it was confirmed today by reiteration of long-term objectives. Baird believe that valuation remains attractive and theu maintain their Outperform rating and $134 price target on Cardinal Health shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH: